Amendment #2
                                ------------

	By this Amendment, Duke University ("DUKE") and CISTRON
Biotechnology, Inc. ("SPONSOR") agree to amend the terms of the Clinical
Study and Research Agreement entered into by the parties effective
September 1, 1998, ("Agreement") and first amended on December 18, 1998 as
follows:

        1. The parties agree that article 1, Statement of Work, shall be
expanded to include the research described in an additional
Statement of Work, a copy of which is attached to the Agreement as
Exhibit C.  The parties also agree that the SPONSOR shall provide
additional compensation to DUKE for the research set forth in
Exhibit C in accordance with the terms described in the supplemental
budget attached to this Agreement as Exhibit D.

        2. The parties agree that Article 1 will be further expanded to
include the research described in the Statement of Work attached to this
Agreement as Exhibit E.  Likewise, the parties agree that SPONSOR
shall provide additional compensation to DUKE for the research set
forth in Exhibit E in accordance with the terms described in the
supplemental budget attached to this Agreement as Exhibit F.

        3. The parties agree that the term of the Clinical Study and Research
Agreement shall be extended through December 31, 9999 and may be
extended beyond that date by mutual agreement of both parties.

        4. All other terms of the Agreement are unchanged and remain in full
force and effect.

AGREED:

DUKE UNIVERSITY                                 SPONSOR

By: /s/RALPH SNYDERMAN, M.D.                    By: /s/BRUCE C. GALTON
   ------------------------                        ------------------
       Ralph Snyderman, M.D.                        Bruce C. Galton
    Chancellor for Heath Affairs                    Chairman and CEO

Date executed: 3/17/99                          Date executed: 3-22-99

Acknowledged:

By: /s/Herman F. Staats       3/19/99
   --------------------
       Herman Staats, Ph.D.
       Principal Investigator